Streptomyces spectabilis strain:NRRL 2792 | isolate:Upjohn Company Genome sequencing

Streptomyces spectabilis NRRL 2792, was isolated and characterized by The Upjohn Co. and submitted to ATCC and NRRL culture collections. Our group subsequently identified and characterized metacycloprodigiosin as another secondary metabolite of S. spectabilis NRRL 2792, which drew our attention since various prodigiosins have been studied as anti-malarial and anti-cancer therapeutics. It was of interest to understand the capacity of the NRRL 2792 strain to express uncharacterized, or cryptic secondary metabolites. Here, we report the first completed genomic sequence of S. spectabilis NRRL 2792 strain. A combination of antiSMASH and BLAST bioinformatics were applied to the genomic sequence to illuminate untapped potential of S. spectabilis NRRL 2792 to express novel SM-BGCs.